GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

ImmuPharma IMM.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

3.24p

-1.52%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in GBP, from our data supplier.

FY2025

Revenue

—

FY2016FY2025

Net income

−£1.8m

FY2016FY2025

Free cash flow

−£2.4m

FY2016FY2025

Shareholders' equity

£686,862

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue————£118,350£126,667£77,925£81,281£150,462£164,784
Research and development£1.3m£1.2m£2.0m£2.0m£3.6m£2.4m£2.7m£4.7m£5.1m£5.3m
Operating income−£2.5m−£2.3m−£3.1m−£3.0m−£8.7m−£5.6m−£6.3m−£8.1m−£7.2m−£6.6m
Net income−£1.8m−£2.5m−£2.9m−£3.8m−£8.2m−£6.9m−£6.1m−£7.2m−£6.2m−£5.3m
Diluted earnings per share-0.00-0.01-0.01-0.01-0.03-0.03-0.04-0.05-0.05-0.04

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets£1.9m£977,011£2.7m£4.0m£6.0m£10.9m£5.8m£8.7m£5.0m£6.7m
Cash and short-term investments£1.4m£236,902£208,481£667,813£1.6m£5.9m£1.4m£4.9m£2.7m£1.9m
Total liabilities£1.2m£1.5m£1.7m£1.5m£1.6m£1.3m£531,867£1.0m£1.4m£1.2m
Debt———£111£700£641,841£26,778£120,810£259,690£362,554
Shareholders' equity£686,862−£542,859£1.1m£2.5m£4.4m£9.7m£5.3m£7.6m£3.6m£5.5m
Shares outstanding491m416m391m318m252m225m167m139m132m123m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−£2.4m−£1.8m−£1.4m−£2.3m−£4.8m−£3.3m−£4.2m−£4.7m−£4.4m−£6.5m
Capital spending−£1,656−£1,652−£2−£106,009−£50,934−£360,290−£107,111−£102,880−£25,491−£4,731
Free cash flow−£2.4m−£1.8m−£1.4m−£2.5m−£4.9m−£3.7m−£4.3m−£4.8m−£4.4m−£6.5m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024
Operating income−£1.1m−£1.3m−£1.2m−£614,916−£1.5m−£956,000−£764,227−£382,000
Net income−£4.7m£31,214−£919,438−£919,438−£1.0m−£1.0m−£194,000−£194,000
Diluted earnings per share-0.010.00-0.00-0.00-0.00-0.00-0.00-0.00
Cash from operations—−£1.0m−£1.0m—————
Total assets£3.1m£1.9m£1.6m£1.6m£977,011£977,011£4.1m£4.1m
Cash and short-term investments£695,836£1.4m£396,648£396,648£236,902£236,902£1.1m£1.1m
Shareholders' equity£1.8m£686,862£336,699£336,699−£542,859−£542,859£2.7m£2.7m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-5.7%-14.6%-5.7%
Net income-22.0%-23.4%-7.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-16.8-2.0-2.2-1.5-2.0-4.4-4.4-2.3-8.4-2.8
Price to sales————140.5237.5343.8201.6348.890.6

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.